These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28123387)

  • 1. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.
    Jiang Z; Jiang X; Chen S; Lai Y; Wei X; Li B; Lin S; Wang S; Wu Q; Liang Q; Liu Q; Peng M; Yu F; Weng J; Du X; Pei D; Liu P; Yao Y; Xue P; Li P
    Front Immunol; 2016; 7():690. PubMed ID: 28123387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
    Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
    Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
    Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
    Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
    J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
    Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
    Front Immunol; 2022; 13():963031. PubMed ID: 36059488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
    Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
    BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.
    Cao G; Zhang G; Liu M; Liu J; Wang Q; Zhu L; Wan X
    Biochem Biophys Rep; 2022 Sep; 31():101324. PubMed ID: 36032401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts.
    Zhuo J; Lu D; Wang J; Lian Z; Zhang J; Li H; Cen B; Wei X; Wei Q; Xie H; Xu X
    Chin J Cancer Res; 2021 Aug; 33(4):470-479. PubMed ID: 34584372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.
    Guo X; Jiang H; Shi B; Zhou M; Zhang H; Shi Z; Du G; Luo H; Wu X; Wang Y; Sun R; Li Z
    Front Pharmacol; 2018; 9():1118. PubMed ID: 30327605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.
    Zhou L; Li Y; Zheng D; Zheng Y; Cui Y; Qin L; Tang Z; Peng D; Wu Q; Long Y; Yao Y; Wong N; Lau J; Li P
    Mol Ther Oncol; 2024 Jun; 32(2):200817. PubMed ID: 38882528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of GPC3-CAR-NK cells and optimization as a therapy for HCC.
    Cao B; Ni Q; Chen Z; Yang S; Zhang X; Su H; Zhang Z; Zhao Q; Zhu X; Liu M
    J Leukoc Biol; 2024 Jun; ():. PubMed ID: 38922297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells.
    Zhao J; Lin L; Luo Y; Cai Q; Jiang X; Liao C; Wei H
    Bioengineered; 2021 Dec; 12(1):3674-3683. PubMed ID: 34261411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
    Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
    PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma.
    Guan L; Wu S; Zhu Q; He X; Li X; Song G; Zhang L; Yin X
    Biochem Biophys Rep; 2024 Sep; 39():101741. PubMed ID: 38881757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.
    Zheng X; Liu X; Lei Y; Wang G; Liu M
    Front Oncol; 2022; 12():824208. PubMed ID: 35251989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.